Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aspire Biopharma Holdings, Inc. - Common Stock (NQ:ASBP)

0.1214 -0.0336 (-21.68%)
Streaming Delayed Price Updated: 12:23 PM EDT, May 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aspire Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record
Via ACCESS Newswire
News headline image
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors
Via ACCESS Newswire
News headline image
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements
Via ACCESS Newswire
News headline image
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Via ACCESS Newswire
News headline image
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit
Via ACCESS Newswire
News headline image
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution
Via ACCESS Newswire
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity
Via ACCESS Newswire
News headline image
Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign
Via ACCESS Newswire
News headline image
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief
Via ACCESS Newswire
Which stocks are moving on Thursday? ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Top movers analysis in the middle of the day on 2026-01-14: top gainers and losers in today's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Aspire Biopharma Announces Reverse Stock Split
Via ACCESS Newswire
Most active stocks in Thursday's session ↗
Via Chartmill
Here are the top movers in Thursday's session. ↗
Via Chartmill
Check out the stocks that are attracting the most attention and driving market activity. ↗
Via Chartmill
News headline image
ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin –  Retail Expects Licensing Negotiations Soon ↗
The FDA’s feedback supports a planned new drug application submission in the second half of 2026. 
Via Stocktwits
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
Wednesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)
Via ACCESS Newswire
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine
Via ACCESS Newswire
News headline image
Brookmount Gold (OTC: BMXI) Profitable Q3 2025, Gold Production, Spinoff Dividends Takes Shape – More Stocks Inside
Via AB Newswire
News headline image
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
Via ACCESS Newswire
News headline image
Aspire Biopharma Provides Q3 2025 Business Update
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.